Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

Ginger.io announces $6.5M Series A funding

Ginger.io, the behavioral health analytics startup, today announced a $6.5 million Series A funding round led by Khosla Ventures.

29 Nov 2012

$ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction$

ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction

A novel study from Karolinska Institutet in Sweden suggests that commonly used drugs to treat heart failure and high blood pressure may have a wider range of application than earlier known, and also can be used against so called HFPEF - a type of heart failure that until now has been impossible to treat.

29 Nov 2012

Digoxin for atrial fibrillation questioned

Experts are calling into question the widespread use of digoxin for atrial fibrillation, in the wake of findings linking the drug to increased mortality.

28 Nov 2012

Diptheria-tetanus-pertussis vaccine: an interview with Dr. Rudi Eggers, World Health Organisation

The Diptheria-tetanus-pertussis vaccine is sometimes also called the “triple vaccine” and has been around for about 50 years, and it protects against diphtheria, tetanus, and pertussis. These are serious diseases caused by bacteria.

28 Nov 2012

Digoxin increases risk of death in patients with atrial fibrillation

Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University of Kentucky researchers. The results have been published in the prestigious European Heart Journal, and raises serious concerns about the expansive use of this long-standing heart medication in patients with AF.

28 Nov 2012

Intramyocardial injection of organ-derived stem cells after AMI improves left ventricle function

A study published in the current issue of Cell Transplantation, now freely available on-line, has found that when mesenchymal cells derived from skeletal muscle (SM-MSCs) or adipose tissue (ADSCs) were injected into the heart muscle (myocardium) of separate groups of laboratory rats that had suffered a myocardial infarction, rats in both groups experienced significantly improved left ventricle function and smaller infarct size after cell therapy.

28 Nov 2012

Moderate exercise protects elderly hearts

The more exercise taken by individuals aged 65 years and older, the less likely biomarkers indicative of cardiac injury and new-onset heart failure are to increase, show US study findings.

26 Nov 2012

Smoking-related diabetes a modifiable risk factor

Cigarette smoking is a modifiable risk factor for impaired insulin secretion in Japanese men, show study findings.

23 Nov 2012

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Patients with active rheumatoid arthritis are as likely to persist with adalimumab treatment as they are with etanercept, show the results of a 2-year randomized efficacy and discontinuation study of the two tumor necrosis factor inhibitors.

23 Nov 2012

Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure Cardiopoietic Regenerative Therapy trial

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.

22 Nov 2012

HeartWare receives FDA approval for new left ventricular assist device

The U.S. Food and Drug Administration today approved the HeartWare Ventricular Assist System, a left ventricular assist device (LVAD), to support heart function and blood flow in patients with end-stage heart failure who are awaiting a heart transplant.

21 Nov 2012

Facts about Homecare

Millions of seniors and people living with disabilities will enjoy Thanksgiving and other holidays in the comfort and safety of their own homes thanks to home medical equipment and services such as oxygen therapy, hospital beds, and wheelchairs.

21 Nov 2012

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

Bristol-Myers Squibb and Pfizer announced today that the European Commission has approved ELIQUIS (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors.

21 Nov 2012

FDA approves HeartWare Ventricular Assist System to treat end-stage heart failure

HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.

20 Nov 2012

Sociologic factors predict time to discharge in lower limb amputees

Sociologic factors such as marital status and living location before hospitalization are key predictors of time to discharge in male veterans after lower extremity amputation, report researchers.

20 Nov 2012

Neurologist care lowers risk for PD-related hospitalizations

Regular care by a neurologist lowers the risk for hospitalization for Parkinson's disease-related complications, US research shows.

20 Nov 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

Treatment-related heart failure risk for rheumatoid arthritis patients revealed

Rheumatoid arthritis patients have no greater risk for heart failure with tumor necrosis factor-alpha therapy than with nonbiologic disease-modifying antirheumatic drugs, research suggests.

19 Nov 2012

Study illuminates how Aldo and galectin-3 protein contribute to vascular remodeling, CHF

Cardiovascular disease will kill nearly 2.5 million people in the United States this year, according to the Centers for Disease Control. Over time, inflammation, collagen deposition and scar tissue formation can cause blood vessels to stiffen, a process called vascular fibrosis. Though researchers have known that the hormone aldosterone (Aldo) plays a role in this process, the precise mechanisms have been poorly understood.

17 Nov 2012

Heart Failure News and Research

Further Reading

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

Ginger.io announces $6.5M Series A funding

ACE-inhibitors, angiotensin receptor blockers can treat heart failure with preserved ejection fraction

Digoxin for atrial fibrillation questioned

Diptheria-tetanus-pertussis vaccine: an interview with Dr. Rudi Eggers, World Health Organisation

Digoxin increases risk of death in patients with atrial fibrillation

Intramyocardial injection of organ-derived stem cells after AMI improves left ventricle function

Moderate exercise protects elderly hearts

Smoking-related diabetes a modifiable risk factor

Rheumatoid arthritis patients adhere to both adalimumab, etanercept

Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure Cardiopoietic Regenerative Therapy trial

HeartWare receives FDA approval for new left ventricular assist device

Facts about Homecare

Pfizer, Bristol-Myers Squibb receive EC approval for ELIQUIS to prevent NVAF-related stroke

FDA approves HeartWare Ventricular Assist System to treat end-stage heart failure

Sociologic factors predict time to discharge in lower limb amputees

Neurologist care lowers risk for PD-related hospitalizations

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Treatment-related heart failure risk for rheumatoid arthritis patients revealed

Study illuminates how Aldo and galectin-3 protein contribute to vascular remodeling, CHF

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News